Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
50,000
Stocks News & Analysis
stocks
Cheap ASX share pays a heavy price for NRL rights
Growth has slowed amid increased competition for viewers and content.
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
Market concerns over governance and AI fears have left shares trading well below the fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.70 | 34.90 | 0.39% |
| CAC 40 | 8,338.97 | 12.35 | 0.15% |
| DAX 40 | 25,067.09 | 51.18 | -0.20% |
| Dow JONES (US) | 52,637.01 | 149.60 | 0.29% |
| FTSE 100 | 10,497.29 | 24.84 | 0.24% |
| HKSE | 24,175.12 | 144.94 | 0.60% |
| NASDAQ | 26,281.61 | 74.72 | 0.29% |
| Nikkei 225 | 68,557.73 | 813.88 | 1.20% |
| NZX 50 Index | 13,785.67 | 120.49 | 0.88% |
| S&P 500 | 7,575.39 | 31.75 | 0.42% |
| S&P/ASX 200 | 8,806.00 | 38.20 | 0.44% |
| SSE Composite Index | 3,996.16 | 40.43 | -1.00% |